These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36251553)

  • 21. Survival of Patient With Hemorrhagic Meningitis Associated With Inhalation Anthrax.
    Lombarte Espinosa E; Villuendas Usón MC; Arribas García J; Jado García I; Huarte Lacunza R; Zárate Chug P; Claraco Vega LM; Jesús Santed Andrés M; Ríos MJ; Cook R; Simard JM; Boyer AE; Rezusta A
    Clin Infect Dis; 2022 Oct; 75(Suppl 3):S364-S372. PubMed ID: 36251557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative pre-approved and novel therapies for the treatment of anthrax.
    Head BM; Rubinstein E; Meyers AF
    BMC Infect Dis; 2016 Nov; 16(1):621. PubMed ID: 27809794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.
    Meaney-Delman D; Zotti ME; Creanga AA; Misegades LK; Wako E; Treadwell TA; Messonnier NE; Jamieson DJ;
    Emerg Infect Dis; 2014 Feb; 20(2):. PubMed ID: 24457117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update: investigation of bioterrorism-related inhalational anthrax--Connecticut, 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(47):1049-51. PubMed ID: 11808925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins.
    Slay RM; Cook R; Hendricks K; Boucher D; Merchlinsky M
    Clin Infect Dis; 2022 Oct; 75(Suppl 3):S441-S450. PubMed ID: 36251555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacillus anthracis as an agent of bioterrorism: a review emphasizing surgical treatment.
    Binkley CE; Cinti S; Simeone DM; Colletti LM
    Ann Surg; 2002 Jul; 236(1):9-16. PubMed ID: 12131080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From the Centers for Disease Control and Prevention. Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis.
    JAMA; 2001 Nov; 286(20):2536-7. PubMed ID: 11763846
    [No Abstract]   [Full Text] [Related]  

  • 28. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax.
    Yamamoto BJ; Shadiack AM; Carpenter S; Sanford D; Henning LN; Gonzales N; O'Connor E; Casey LS; Serbina NV
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5796-805. PubMed ID: 27431219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric anthrax clinical management.
    Bradley JS; Peacock G; Krug SE; Bower WA; Cohn AC; Meaney-Delman D; Pavia AT;
    Pediatrics; 2014 May; 133(5):e1411-36. PubMed ID: 24777226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From the Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related inhalation anthrax--Connecticut, 2001.
    JAMA; 2001 Dec; 286(23):2936-7. PubMed ID: 11787482
    [No Abstract]   [Full Text] [Related]  

  • 31. Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(44):973-6. PubMed ID: 11724150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. When bioterrorism strikes: diagnosis and management of inhalational anthrax.
    Shafazand S
    Semin Respir Infect; 2003 Sep; 18(3):134-45. PubMed ID: 14505276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anthrax as a biological weapon, 2002: updated recommendations for management.
    Inglesby TV; O'Toole T; Henderson DA; Bartlett JG; Ascher MS; Eitzen E; Friedlander AM; Gerberding J; Hauer J; Hughes J; McDade J; Osterholm MT; Parker G; Perl TM; Russell PK; Tonat K;
    JAMA; 2002 May; 287(17):2236-52. PubMed ID: 11980524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
    Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
    J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case report of inhalation anthrax acquired naturally.
    Azarkar Z; Bidaki MZ
    BMC Res Notes; 2016 Mar; 9():141. PubMed ID: 26939756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pediatric anthrax clinical management: executive summary.
    Bradley JS; Peacock G; Krug SE; Bower WA; Cohn AC; Meaney-Delman D; Pavia AT;
    Pediatrics; 2014 May; 133(5):940-2. PubMed ID: 24777221
    [No Abstract]   [Full Text] [Related]  

  • 37. Human anthrax as a re-emerging disease.
    Doganay M; Demiraslan H
    Recent Pat Antiinfect Drug Discov; 2015; 10(1):10-29. PubMed ID: 25851429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhalational anthrax and bioterrorism.
    Quintiliani R; Quintiliani R
    Curr Opin Pulm Med; 2003 May; 9(3):221-6. PubMed ID: 12682568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacillus anthracis.
    Spencer RC
    J Clin Pathol; 2003 Mar; 56(3):182-7. PubMed ID: 12610093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Oct; 50(41):889-93. PubMed ID: 11686472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.